IκBε deficiency accelerates disease development in chronic lymphocytic leukemia

Area of Science:

• * Hematology
• * Molecular Biology
• * Oncology

Background:

• * The NFKBIE gene, encoding the NF-κB inhibitor IκBε, is altered in 3-7% of chronic lymphocytic leukemia (CLL) patients.
• * A common 4-bp deletion in NFKBIE leads to NF-κB activation, poor prognosis, and aggressive disease in CLL.
• * Understanding NFKBIE's role is crucial for developing targeted therapies for CLL.

Purpose of the Study:

• * To investigate the functional consequences of NFKBIE gene inactivation in chronic lymphocytic leukemia (CLL).
• * To explore the role of NFKBIE in controlling NF-κB activity, disease expansion, and therapeutic resistance in CLL.
• * To assess the impact of IκBε deficiency on CLL cell migration, proliferation, and overall disease progression.

Main Methods:

• * Engineered CLL B cells and CLL-prone mice to stably down-regulate NFKBIE expression.
• * Utilized in vitro and in vivo models to study the effects of NFKBIE inactivation.
• * Performed RNA-sequencing on NFKBIE-mutated patient samples to analyze pathway alterations.

Main Results:

• * NFKBIE loss activates the NF-κB pathway, promoting CLL cell migration and proliferation in a dose-dependent manner.
• * NFKBIE inactivation accelerated CLL clone expansion in lymphoid organs, leading to aggressive disease and reduced survival in mouse models.
• * IκBε deficiency correlated with MAPK pathway alterations and resistance to the BTK inhibitor ibrutinib in CLL.

Conclusions:

• * The NF-κB pathway plays a significant role in CLL pathogenesis and progression.
• * NFKBIE inactivation drives aggressive CLL phenotypes and confers resistance to ibrutinib.
• * Findings provide a basis for novel therapeutic strategies targeting the NF-κB pathway in CLL.